Skip to content
clinical trials
-
Eli Lilly’s Jaypirca reduces the risk of disease progression by 80% in first-line CLL trials
The study compared the drug against bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who had not received prior treatment and did not have 17p deletions.
-
FDA issues draft guidance to reduce primate testing in monoclonal antibody development
Macaque monkeys serve as the most common species for drug testing because they share considerable physiological similarities with humans.
-
Genmab halts phase 1/2 trial for oncology candidate GEN1160 amid broader strategic review
GEN1160 now joins GEN1107 on Genmab’s list of discontinued assets from the April 2024 ProfoundBio acquisition.